Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since posts 31–60

Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.

I have left out the parts I could not verify.

On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.

It reads as pedantry until the day it does not.

Where I part company with post #31, and it is a narrow parting.

Taking Semaglutide half-life seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison, and those two things support very different sentences.

Post #31 is the version of this I will quote in future. One addition.

Discontinuation rates in the trials are worth reading alongside efficacy and almost never are. A large mean effect in a population where a meaningful fraction stopped early is telling you two things, not one.

The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

It is a small point and it changes the answer, which is an awkward combination.

Picking up post #35: that is the part I would want checked first.

Two people in this thread mean different things by Semaglutide half-life and are disagreeing about the definition while believing they are disagreeing about the facts. Worth pausing to define it.

I had written a reply contradicting post #35 and deleted it. Here is what survived.

Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate, fibres or frank cloudiness are a different observation entirely and are worth raising with the supplier rather than reasoning about.

On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.

Worth separating two things that post #35 runs together.

Nobody has said the unglamorous part of Semaglutide half-life yet, so: most of the variation is explained by things that are boring to write about and easy to check.

This follows post #39 rather than contradicting it.

Answering the Semaglutide half-life question as asked, then the question I think is meant. As asked: yes, with the qualification below. As meant: it depends on how the first measurement was taken.

On formulation: the licensed product is buffered and includes a preservative in the multi-dose presentation. A reconstituted research preparation matches neither, and stability claims made about the first do not carry over to the second.

That is my reading. Someone else read the same page differently and was reasonable.

Coming back to post #38, because the follow-up matters more than the original answer.

My experience of Semaglutide half-life contradicts the reply above. I am posting it as a data point rather than as a refutation, because one person's experience is exactly that.

Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about what it is, not a coded opinion about anything.

Happy to expand any of that if it is the useful part.

Understood. Thank you for being specific about the limits of it.